Holen Sie sich die Stockscreener-App
25.14
0.12%
0.03
Handel nachbörslich:
25.14
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$25.11
Offen:
$25.22
24-Stunden-Volumen:
31.78M
Relative Volume:
0.78
Marktkapitalisierung:
$142.93B
Einnahmen:
$63.83B
Nettoeinkommen (Verlust:
$10.77B
KGV:
13.37
EPS:
1.88
Netto-Cashflow:
$12.44B
1W Leistung:
+2.28%
1M Leistung:
+2.15%
6M Leistung:
-1.53%
1J Leistung:
-12.43%
1-Tages-Spanne:
$24.97
$25.30
1-Wochen-Bereich:
$24.47
$25.30
52-Wochen-Spanne:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.14 | 142.76B | 63.83B | 10.77B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
701.23 | 613.56B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.64 | 420.78B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
206.69 | 361.58B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
124.21 | 236.35B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.21 | 206.72B | 63.43B | 16.42B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer's Value Re-rating: Can Strong Institutional Interest and a Revitalized R&D Pipeline Justify a Buy? - AInvest
Citi Raises PT on Pfizer Inc. (PFE) to $26; Maintains ‘Neutral’ Rating - uk.finance.yahoo.com
Padcev plus Keytruda significantly improves survival for certain patients with bladder cancer when given... - Medical Dialogues
Pfizer's Sickle Cell Drug Fails to Meet Main Goal, Safety Profile Remains a Potential Asset - AInvest
2 Top Dividend Stocks to Buy on the Dip - The Motley Fool
Can Pfizer Inc. maintain its current growth rateJuly 2025 Macro Moves & Intraday High Probability Setup Alerts - thegnnews.com
Is Pfizer's Turnaround Real, and Is the 6.5% Dividend Safe? - AInvest
Pfizer: This Is What Bulls Waited For - Seeking Alpha
Pfizer Reports Positive Topline Phase 3 Results For HYMPAVZI™ In Hemophilia A or B With Inhibitors - MSN
Pfizer’s Phase 3 Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis Treatment - MSN
Pfizer and AbbVie Advance Pediatric Antibiotic Study: Market Implications - MSN
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings - MSN
Pfizer’s Pediatric Migraine Study: A Potential Game-Changer? - MSN
Pfizer’s Tukysa Study: A Closer Look at Its Korean Market Impact - MSN
Pfizer’s Talzenna®: New Korea PMS Study Update and Market Insights - TipRanks
Pfizer’s Promising Migraine Study: A New Hope for Adolescents - TipRanks
A US FDA Move to Revoke Pfizer’s Pediatric COVID-19 Vaccine EUA Could Raise Supply Questions - insights.citeline.com
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell DiseasePfizer (NYSE:PFE) - Benzinga
Pfizer’s sickle-cell treatment efforts falter as drug fails study - WHTC
Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer - uk.finance.yahoo.com
Pfizer’s sickle cell drug candidate fails Phase 3 trial - Endpoints News
Pfizer Gets Another Dose of Disappointment as Sickle Cell Disease Drug Fails Pivotal Test - MedCity News
Pfizer’s Pediatric Sickle Cell Study: Key Updates and Market Implications - TipRanks
Pfizer's Sickle Cell Setback: Assessing Pipeline Resilience and Strategic Realignments in a High-Stakes R&D Landscape - AInvest
Pfizer’s Promising Phase 3 Study on Ritlecitinib for Vitiligo: A Potential Game-Changer - TipRanks
Pfizer’s CIBINQO Pregnancy Study: Safety Insights and Market Impact - TipRanks
Pfizer’s New Cancer Treatment Study: A Potential Game Changer? - TipRanks
Pfizer’s New Study on Eczema Treatment: What Investors Need to Know - TipRanks
Pfizer's sickle-cell treatment efforts falter as drug fails study - Reuters
Pfizer and BioNTech’s Combined Vaccine Study: A Potential Game-Changer - TipRanks
Pfizer’s Abrocitinib Study: Real-World Insights into Atopic Dermatitis Treatment - TipRanks
Pfizer says phase 3 Thrive-131 study did not meet its primary endpoint - MarketScreener
Pfizer’s New Pediatric Eczema Study: A Potential Game-Changer? - TipRanks
Pfizer’s Marstacimab Trial: A New Hope for Pediatric Hemophilia Treatment? - MSN
Pfizer’s Promising Study on PF-07248144: A Potential Game-Changer in Cancer Treatment - TipRanks
Pfizer’s Latest Clinical Trial: A New Hope for KRAS-Mutated Tumors - TipRanks
Pfizer’s Zavicefta Study: Ensuring Safety and Efficacy in Korea - TipRanks
Pfizer’s New Phase 1 Trial: A Potential Game-Changer in Oncology? - TipRanks
Pfizer’s Phase 3 Study on Elranatamab: A Potential Game-Changer for Multiple Myeloma Treatment - TipRanks
Pfizer’s New Phase 1 Study on PF-07832837: A Potential Game-Changer for Atopic Dermatitis - TipRanks
Pfizer’s New Phase 3 Study: A Potential Game-Changer in Breast Cancer Treatment - TipRanks
Pfizer experimental sickle cell drug fails phase 3 trialCNBC - MarketScreener
Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial - BioPharma Dive
Pfizer's sickle cell drug fails late-stage trial - Reuters
Pfizer's sickle cell drug fails main goal in late-stage trial - Reuters
Pfizer fails in late-stage trial for sickle cell disease therapy - Seeking Alpha
Pfizer Inc. Approaches Psychological Resistance LevelJuly 2025 Trends & Weekly Breakout Opportunity Watchlist - newsyoung.net
After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again? - AOL.com
Rx Rundown: Bayer, BlinkRx, Pfizer and more - Medical Marketing and Media
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.55%
2.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):